Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00941031 · ClinicalTrials.gov registry record · Phase 2
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Phase 2 study of Chronic Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 404
- Enrollment target
- 20
- Study locations
NCT00941031 is a Phase 2 study of Chronic Plaque-type Psoriasis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 404 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT00941031, a Phase 2 study of Chronic Plaque-type Psoriasis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 404 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AIN457
- DRUG AIN457A
Study Locations (20)
California
- Novartis Investigative Site - Pasadena
- Novartis Investigative Site - San Diego
Georgia
- Novartis Investigative Site - Newnan
- Novartis Investigative Site - Snellville
Illinois
- Novartis Investigative Site - Champaign
- Novartis Investigative Site - Springfield
Michigan
- Novartis Investigative Site - Clinton Twp.
- Novartis Investigative Site - Detroit
Nebraska
- Novartis Investigative Site - Omaha
- Novartis Investigative Site - Omaha
Alabama
- Novartis Investigative Site - Birmingham
Arkansas
- Novartis Investigative Site - Little Rock
Indiana
- Novartis Investigative Site - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00941031
The ClinicalTrials.gov registry entry for NCT00941031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Plaque-type Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00941031 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT00941031 about?
NCT00941031 is a clinical study titled "AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis". The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).
What is the current status of trial NCT00941031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 404 participants. The study started on 2009-07. Estimated completion is 2010-12.
What conditions does trial NCT00941031 study?
This clinical trial studies the following conditions: Chronic Plaque-type Psoriasis.
What interventions are being tested in trial NCT00941031?
The interventions under investigation include: Placebo (DRUG), AIN457 (DRUG), AIN457A (DRUG).
Who is sponsoring clinical trial NCT00941031?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00941031 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.